Lecanemab’s five-year report card lands in Boston
Eisai’s CTAD slate includes five-year Clarity AD data, a real-world symposium and a look at lecanemab and donanemab dosing. Anybody on an anti-amyloid drug has probably wondered, at some point, whether they’ll ever get to stop. Eisai has a poster on exactly that. It’s numbered P001, it sits first on
<p>Eisai’s CTAD slate includes five-year Clarity AD data, a real-world symposium and a look at lecanemab and donanemab dosing. Anybody on an anti-amyloid drug has probably wondered, at some point, whether they’ll ever get to stop. Eisai has a poster on exactly that. It’s numbered P001, it sits first on</p>